Here's Why Novartis (NVS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis gene therapy helps children with rare muscle disorder in study
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow.
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya.
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected.
NVS vs. LLY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Novartis (NVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novartis: Time To Increase
Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of consensus.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast cancer; Study to start mid-2025. Data from ongoing phase 3 OPERA-01 study, using palazestrant alone as a monotherapy to target patients with ER+/HER2- metastatic breast cancer, expected in 2026. The global breast cancer market size is predicted to surpass $89.01 billion by 2034.
